Fresh From IPO, Five Prime Therapeutics, Inc. Advances Arthritis And Cancer Drugs

Published: Dec 19, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Investors in healthcare’s big IPO class of 2013 have seen some wild swings in share values since the debuts of dozens of new public companies. Hot trading in the Cambridge, MA-based companies Foundation Medicine and Epizyme pushed their peak prices above $40 for a time, followed by declines that sent the stocks swooning below their initial closing prices. Redwood City-based Relypsa’s shares roughly doubled in value in less than a month.

Help employers find you! Check out all the jobs and post your resume.

Back to news